Laurent Bertoletti Highlights Evolving Role of Anticoagulation in Pulmonary Hypertension Treatment
Laurent Bertoletti, University Professor and Hospital Practitioner at Jean Monnet University, Saint-Etienne, shared on LinkedIn:
”Thank you to the scientific council of the French Days of Pulmonary Hypertension RespiFil for the invitation to present an update on the treatment anticoagulant in pulmonary hypertension.
It is an honour to be able to share data from the French registry and to discuss a topic that is as debated as it is crucial for patient care.
The prescription of anticoagulants now seems to be restricted to patients with a validated indication such as a history of MTEV or atrial fibrillation.
The next collective objective is to determine the best therapeutic antithrombotic strategy, in patients with PH-TEC or PH and a validated indication.”
Stay updated with Hemostasis Today.
-
Apr 25, 2026, 02:33Sara Zalghout: Platelet Glycans as Diagnostic and Therapeutic Targets
-
Apr 25, 2026, 02:20Pierpaolo Di Micco: Proud to Be Published in JAMA for the Third Time in Four Years
-
Apr 25, 2026, 02:11Kathryn Golab: Coagulation QA Essentials for Reliable Lot to Lot Testing
-
Apr 24, 2026, 23:36Pedro Perez: Are We Measuring the Right Outcomes in VTE?
-
Apr 24, 2026, 20:41Christine Ngaruiya: Malvika Krishnamurthy Highlights Biomarker Gaps in Stroke Research at Stanford Research Symposium
-
Apr 24, 2026, 17:58Erwin Loh: Triple Combination Therapy Shows Major Benefit in Preventing Recurrent Stroke
-
Apr 24, 2026, 17:51Mostafa Faisal Mohammed Saleh: Exploring the Impact of PNH Clones in Aplastic Anemia Across Different Treatment Strategies
-
Apr 24, 2026, 17:35Dawn Faller: Strengthening Global Collaboration in Apheresis at the 2026 ASFA and WAA Joint Meeting
-
Apr 24, 2026, 17:30Omar Adwan: Easy-to-Remember Tips for MCV